Abstract: Ginseng, the root of Panax species, is a well-known herbal medicine. It has been used as traditional medicine in Korea, China and Japan for thousands of years and now is a popular and worldwide natural medicine. The active principles of ginseng are ginsenosides which are also called ginseng saponins. Traditionally ginseng has been used primarily as a tonic to invigorate weak body functions and help the restoration of homeostasis. Current in vivo and in vitro studies demonstrate its beneficial effects in a wide range of pathological conditions such as cardiovascular diseases, cancer, immune deficiency and hepatotoxicity. Moreover, recent research indicates that some of ginseng’s active ingredients exert beneficial actions on aging and neurodegenerative disorders such as Parkinson’s disease. Essentially, antioxidant, anti-inflammatory, anti-apoptotic and immunostimulant activities are mostly underlying the postulated ginseng-mediated protective mechanisms. Next to animal studies, data from neural cell cultures contribute to the understanding of these mechanisms which involve decreasing nitric oxide, scavenging of free radicals and counteracting excitotoxicity. This paper focuses on own and other neuroprotective data on ginseng for dopaminergic neurons and intends to show aspects where neuroprotection e.g. by ginsenosides, additionally or preceding standard Parkinson therapy, could come about as a valuable contribution to slow neurodegenerative processes.

Key words: Ginsenosides, Parkinson’s disease, dopaminergic, neuroprotection

INTRODUCTION

Parkinson’s disease (PD) as a common progressive neurodegenerative disorder is characterised by massive depletion of striatal dopamine as a result of the degeneration of dopaminergic neurons in the substantia nigra. Clinically, the disease is manifested by bradykinesia, resting tremor, rigidity and disturbance of posture and gait[1]. However still to date, the etiopathogenesis of nigral dopaminergic neuron loss in PD is unclear. The presence of ongoing oxidative stress as the result of inefficacious antioxidant defence mechanisms and generation of radical oxygen species in the substantia nigra of the parkinsonian brain are important pathogenetic mechanisms[2]. It should be noted that part of these free radicals are inevitably produced by dopamine metabolism in the brain either enzymatically through the action of monoamine oxidase B or by autooxidation[3,4]. Therefore, an effective anti-parkinsonian therapy should not only alleviate the disease-associated symptoms, but should also interfere with the progressive dopaminergic death in the substantia nigra. Primary cell cultures of mesencephalic dopaminergic neurons have contributed to the understanding of molecular processes when using neurotoxic compounds that mimick cell death in PD. They also have the potential to analyse neuroprotective compounds for their ability to counteract these processes. Ginsenosides as the active ingredients in Panax ginseng are known for their anti-inflammatory, immunostimulant, antioxidative and possibly neurotrophic properties. Given their importance as a medication and health medicine their potential to dopaminergic cells in different PD cell models is analysed. However, it first it appears essential to consider the current therapeutic options and underlying theories of PD therapy to understand the need for further improvements or alternative strategies.
Treatment of Parkinson's disease with levodopa
Since its introduction by Birkmayer and Hornykiewicz\(^5\), levodopa remained the most effective drug for the symptomatic treatment of PD. Its effect for Parkinsonian patients is primarily based on its ability as a dopamine precursor to compensate the decrease of dopamine in the brain. Although the initial use of levodopa replacement therapy is effective in symptomatic treatment of PD, the clinical efficacy often declines after long-term therapy and additionally disabling side-effects appear, notably motor fluctuations such as the wearing-off or on-off phenomena and dyskinesia\(^6\). These motor response complications appear in most patients with advanced PD treated with levodopa. The precise mechanisms for the appearance of these treatment-related fluctuations are not clear. Nutt\(^7\) reported that the long-duration response that characterizes the first few years of levodopa use in Parkinsonian patients appears to depend on the integrity of remaining dopaminergic nerve terminals in the striatum which retain the capacity to synthesize, release, reuptake and store newly synthesized dopamine. After long-term use of levodopa and with progression of the disease, the short-duration response to levodopa and appearance of motor fluctuations are paralleled with dopaminergic denervation and loss of release and reuptake capacity\(^8\).

Effect of levodopa on dopaminergic cells
Though dopamine replacement therapy with levodopa is successful to improve PD symptoms, it does not inhibit the progressive degeneration of dopaminergic neurons in the substantia nigra. Levodopa is not only ineffective against death of dopaminergic cells in PD patients, but there is also serious concern about possible toxic actions of levodopa to the remaining dopaminergic neurons. It has been reported that this compound is toxic to cultured dopaminergic neurons\(^9,10\). On the other hand, there is evidence indicating that large doses of levodopa do not induce dopamine neuron degeneration in mice, rats and human\(^11-13\). In PD patients, it was speculated that the remaining dopaminergic neurons in the patient's brain could be particularly vulnerable to levodopa toxicity since they are hyperactive as a consequence of compensatory mechanisms\(^14\). In contrast, Dziewczapski et al.\(^15\) and Murer et al.\(^16\) reported that treatment of rats with different degree of nigrostriatal damage for 6 months with oral levodopa was not toxic for remaining dopaminergic neurons. Even when levodopa administration is started during an active degenerative process of dopaminergic neurons after intrastratial 6-hydroxydopamine (6-OHDA) injection, no aggravation of toxicity was found\(^17\).

Mechanisms underlying levodopa toxicity
It was reported that increasing oxidative stress via autooxidation of levodopa plays an important role in levodopa toxicity. Autooxidation and metabolism of levodopa can give rise to potentially harmful free radical species, hydrogen peroxide (H\(_2\)O\(_2\)) and quinones\(^18,19\). H\(_2\)O\(_2\) plays the most crucial role in the cascade of oxidative events induced by dopamine or levodopa\(^20\). Quinones were suggested to be responsible in part for the degeneration of non-dopaminergic neurons\(^21\). Their levels correlated positively with the severity of cell death in human neuroblastoma NB69 cells and the damage of dopaminergic neurons took place early before the rising of quinones. In addition to generation of H\(_2\)O\(_2\) and quinone formation, levodopa-induced cell death may result from induction of apoptosis as evidenced by the increase in caspase-3 activity in Neuro-2A cells\(^22\). Taken together, levodopa-induced toxicity is related primarily to dopamine production. Excessive dopamine metabolism by high-dose levodopa therapy may promote oxidative stress and thereby accelerate the rate of neuronal degeneration either in vivo or in vitro. Interestingly, Muriel et al.\(^23,24\) observed that levodopa treatment of control and lesioned rats with 6-OHDA altered the localization of the D\(_1\) dopamine receptor from the plasma membrane into the cytoplasm. The altered localization of D\(_1\) receptors may participate in the occurrence of the side effects of levodopa therapy such as dyskinesia and fluctuations in motor performance.

Dopamine receptors as a target in PD-therapy
Dopamine receptors belong to two classes (D1 and D2) of G protein-coupled receptors. The classification of dopamine receptors is primarily based on their effects on adenylyl cyclase activity and cAMP accumulation in the cells\(^25\). The D1 receptor subtypes promote, whereas the D2 subtypes inhibit adenylyl cyclase activity and cAMP synthesis\(^26\). It has been reported that the D2 receptors are mainly responsible for modulating the activity of voltage-sensitive Ca\(^{2+}\) and K\(^+\) channels\(^27\). Dopamine receptor agonists play an important role in anti-Parkinsonian therapy and have become increasingly popular since the introduction of bromocriptine by Calne and colleagues in 1974\(^28\). Their development aimed at reducing the unwanted motor complications produced by levodopa therapy\(^29\). Dopamine receptor agonists are being used in the initial treatment of patients with de novo PD either as
monotherapy or combined with low doses of levodopa30). Moreover, dopamine agonists are advantageous in several aspects. They do not require carrier-mediated transport in the gut or brain. They act directly on dopamine receptors without the need for metabolic modification, release or storage. They also have longer half-lives than levodopa and therefore produce more persistent dopamine receptor stimulation than levodopa. Their metabolism does not generate free radicals which are considered one of the most important hazards in levodopa treatment particularly on dopaminergic neurons31). The most important dopamine receptor agonists which are currently approved and gained access into the clinic and research studies are ergoline derivatives such as bromocriptine, lisuride, pergolide, cabergoline and á-dihydroergocryptine as well as the recently used non-ergoline derivatives like rotigotine, pramipexole, ropinirole and apomorphine. Ergolines, derivatives of ergot alkaloids, have a longer history in anti-Parkinsonian therapy and are as effective as non-ergolines, which were developed in the hope that they might provide benefits of the ergoline agents without their side effects32). Partly, the individual dopamine agonists show significant variation in their receptor affinity33).

There is increasing evidence in the literature that dopamine agonists are not only beneficial to delay levodopa therapy in early Parkinsonism or to counteract its complications after long-term use but they have also been proposed to be neuroprotective particularly in experimental models34,35). The mechanisms and processes underlying the neuroprotective actions of dopamine agonists appear to be interlaced. They spare levodopa, thereby reducing the formation of oxidative radicals from levodopa metabolism, act as radical scavengers, reduce dopamine synthesis, release and metabolism via activating presynaptic autoreceptors, ameliorate excitotoxicity by suppressing subthalamic nucleus overactivity and exert antiapoptotic effects.

Ginseng – a natural product and its active ingredients

Ginseng refers to the roots of several species in the plant genus Panax (C. A. Meyer Araliaceae). Among them, Panax ginseng is the most widely used ginseng and is indigenous to the Far East countries (most notably Korea and China). Panax ginseng has a medical history of more than five thousand years. The genus name of Panax ginseng “Panax” was given by the Russian botanist C.A. Meyer, and is derived from the Greek words “pan” meaning all and “axos” meaning cure. The species name “ginseng” comes from the Chinese word “rensheng” which means “human” as ginseng roots resemble the human body 36).

Ginsenosides or ginseng saponins are the principle active ingredients in ginseng and more than thirty different ginsenosides have been identified37, 38). They consist of a gonane steroid nucleus with 17 carbon atoms arranged in four rings (see Fig. 1). The characteristic biological responses for each ginsenoside are attributed to the differences in the type, position and number of sugar moieties attached by glycosidic bond at C-3 and C-6 (Fig. 1). Based on their structural differences, they can be classified into three categories: the panaxadiol group (e.g. Rb1, Rb2, Rc, Rd, Rg3, Rh2, Rs1), the panaxatriol group (e.g. Re, Rf, Rg1, Rg2, Rh1), and the oleanolic acid group (e.g. Ro)39,40).

General effects attributed to ginseng

Ginseng products are commonly used as general tonic and adaptogen to help the body to resist the adverse influences of a wide range of physical, chemical and biological factors and to restore homeostasis 36,41). These tonic and adaptogenic effects of ginseng are believed to enhance physical performance including sexual function and general vitality in healthy individuals, to increase the body’s ability to fight stress in stressful circumstances and to support resistance to diseases by strengthening normal body function as well as to reduce the detrimental effects of the aging processes 42,43).

Ginseng rescues neuronal cells either in vivo or in vitro

Recently, it has been shown that ginseng and its components, ginsenosides, have a wide range of actions in the central nervous system44). These effects include increased cell survival, extension of neurite growth and rescuing of
neurons from death due to different insults either in vivo or in vitro. Sugaya et al. (45), Himi et al. (46) and Mizumaki et al. (47) reported that ginseng roots appeared to facilitate survival and neurite extension of cultured cortical neurons and Kim et al. (48) showed that ginsenosides Rb₁ and Rg₃ protected neurons from glutamate-induced neurotoxicity. Following forebrain ischaemia in gerbils, Wen et al. (49) and Lim et al. (50) demonstrated that central infusion of ginsenoside Rb₁ rescued hippocampal CA1 neurons from lethal damage by cellular hypoxia. Using a spinal neuron model, ginsenosides Rb₁ and Rg₁ proved to be effective therapeutic agents for spinal cord injuries as they protected spinal neurons from excitotoxicity induced by glutamate and kainic acid and oxidative stress induced by hydrogen peroxide (51).

Ginseng’s role in Parkinson’s disease models

A number of studies have recently described the beneficial effect of ginseng and its main components, ginsenosides, on different neurodegenerative disease models. Special interest has been paid to PD models either in vivo or in vitro. In an in vivo model, Van Kampen et al. (52) reported that prolonged oral administration of ginseng extract G115 significantly protected against neurotoxic effects of parkinsonism-inducing agents such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite 1-methyl-4-phenylpyridinium (MPP⁺) in rodents. They found that ginseng-treated animals sustained less damage and TH⁺ neuronal loss in substantia nigra pars compacta (SNpc) after MPP⁺ exposure. Likewise reduction of TH immunoreactivity in striatum was effectively diminished as a result of ginseng treatment compared to MPP⁺ exposed animals. Similarly, striatal dopamine transporter (DAT) was significantly preserved due to ginseng treatment.

Our studies have used primary dopaminergic cells (53). Such nerve cell cultures can be prepared from embryonic mouse brains on gestation day 14. These cells grow in serum and later serum-free conditions and differentiate into complex neuronal structures, which can be kept viable up to one month. Dopaminergic cells are characterized by immunohistochemistry as tyrosine hydroxylase positive structures. These cells however only represent a small part in culture and coexist with other neurons (e.g. gabaergic) and glial elements as predominantly astrocytes. Trophic properties by ginsenoside Rb₁ can be demonstrated in our cultures (Fig. 2). The addition of Rb₁ (10 μM) results in 20% increased neurite lengths, a result which indicates growth stimulation or acceleration. As we could show in our previous study (53) MPP⁺ concentrations of 1 μM decrease dopaminergic cell counts by about 40
%. Looking at neurite lengths of dopaminergic cells (Fig. 3) the reduction of cellular processes by MPP⁺ was effectively attenuated by ginsenoside Rb₁. Considering extrapolations of such cell culture data to the in vivo situation could mean that a substantial part of affected neurons can be rescued or kept alive for a longer time span.

As to elucidate the processes and mechanisms underlying the neuroprotective effects of ginseng for dopaminergic neurons, several reports demonstrate the inhibitory role of ginseng on MPP⁺ uptake in dopaminergic neurons, the suppression of oxidative stress induced by autooxidation of dopamine, the attenuation of MPP⁺-induced apoptosis and the potentiation of nerve growth factor action. Ginsenosides inhibit dopamine uptake into rat synaptosomes and consequently ginseng could potentially provide protection against MPP⁺ through blockade of its uptake by dopaminergic neurons. Ginsenoside Rg₁ may interrupt dopamine-induced elevation of reactive oxygen species or nitrogen oxide generation in pheochromocytoma cells. Kim et al. and Chen et al. reported that ginseng attenuated MPP⁺-induced apoptosis as it decreased the intensity of MPP⁺-induced DNA laddering in PC12 cells and ginsenoside Rg₁ had protective effect against MPTP-induced apoptosis in the mouse substantia nigra. This anti-apoptotic effect of ginseng may be attributed to enhanced expression of Bcl-2 and Bcl-xl, reduced expression of bax and nitric oxide synthase and inhibited activation of caspase-3. Ginseng may also reverse the neurotoxic effects of MPP⁺ through elevation of NGF mRNA expression. In accordance, Salim et al. showed that ginsenosides Rb₁ and Rg₁ elevate NGF mRNA expression in rat brain and Rudakewich et al. concluded that both ginsenosides potentiate NGF-induced neurite outgrowth in cell culture. Ginsenosides Rb₁, Rg₁, Rc and Re inhibited tyrosine hydroxylase activity and exhibited anti-dopaminergic action since they reduced the availability of dopamine at presynaptic dopaminergic receptors.

Glutamate as an excitotoxin may contribute to neuronal death in PD

Excitotoxic events could be important triggers for cell death in PD. Given the sensitivity of a disturbed dopaminergic system, overactivities of other transmitter systems may contribute to neurodegeneration. Glutamate is a major neurotransmitter in the mammalian nervous system. It plays an important role in many physiological functions including brain development and learning. On the other hand, glutamate is known to be a potent neurotoxin when present in excess at synapses and glutamate excitotoxicity has been shown to contribute to neuronal degeneration in acute conditions such as stroke, epilepsy, trauma, hypoxia and hypoglycaemia and chronic neurodegenerative diseases such as PD but also Alzheimer’s and Huntington’s diseases and amyotrophic lateral sclerosis. The whole pathogenesis of glutamate toxicity is not fully understood. There is general agreement that it is Ca²⁺ dependent and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors plays a key role in mediating at least a certain aspect of glutamate toxicity. Ca²⁺ loading exceeding the capacity of Ca²⁺ regulating mechanisms could activate several cell death-related genes and pathways. These include calcium-dependent activation of nucleases, lipases, proteases and neuronal nitric oxide synthase thus increasing oxidative stress. In 1992, Albin and Greenamyre introduced the concept of “weak excitotoxicity” postulating that also physiologic concentrations of glutamate can cause an excitotoxic influx of calcium when reduced ATP levels lead to disturbed ionic homeostasis, depolarized membrane potential and consequently release of the voltage-dependent Mg²⁺ blockade of the NMDA receptor, since a defect in complex I activity of the mitochondrial respiratory chain was reported in substantia nigra of Parkinsonian brains. This mechanism might well contribute to the degeneration of dopaminergic neurons. Additionally, increased glutamate release in the substantia nigra might also contribute to the damage of dopaminergic neurons since they are rich in glutamate receptors and receive glutamatergic input from cortex and subthalamic nucleus. The progressive dopamine deficiency during the course of PD is supposed to cause a disinhibition of the subthalamic nucleus thereby increasing excitotoxic damage in the substantia nigra.

Ginsenosides reduce excitotoxicity in vitro

In our studies on glutamate excitotoxicity, primary cultures from embryonic mouse mesencephala were exposed to a neurotoxic glutamate concentration and protective effects of these two ginsenosides on survival and neuritic growth of dopaminergic cells were tested. Treatment of primary mesencephalic culture with 500 µM glutamate for 15 min increased the release of lactate dehydrogenase (LDH) into the culture medium, propidium iodide uptake by the cells and the total number of nuclei with condensed and fragmented chromatin (as apoptotic characteristics) as evaluated with Hoechst 33342. Moreover, glutamate extensively decreased the number of tyrosine hydroxylase immunopositive cells and adversely affected the length and number of their neuronal pro-
cesses. The toxic effect of glutamate was primarily mediated by over-activation of N-methyl-d-aspartate receptor (NMDA) as treatment of cultured cells with (+)MK 801, a NMDA receptor antagonist, nearly abolished the dopaminergic cell loss and LDH release induced by glutamate.

When added alone for six consecutive days (at final concentrations 0.1, 1, 10, 20 µM), ginsenoside Rb\textsubscript{1} (at 10 µM) significantly enhanced the survival of dopaminergic neurons compared to untreated controls. Against glutamate exposure, ginsenosides Rb\textsubscript{1} and Rg\textsubscript{1} could not prevent cell death. However when pre-treating for 4 days or post-treating for 2 days following glutamate exposure, they significantly increased the numbers and lengths of neurites of surviving dopaminergic cells. Fig. 4 shows such a regenerative effect of ginsenoside Rb\textsubscript{1}. When given four days of regeneration following a glutamate insult, cell lengths regenerate about 50% better in the presence of 10 µM Rb\textsubscript{1}. Thus our study indicates that ginsenosides Rb\textsubscript{1} and Rg\textsubscript{1} exert partial neurotrophic and neuroprotective effects in dopaminergic cell culture.

**Effect on neurotransmitter changes by ginsenosides**

PD has biochemically been characterized as a loss of dopamine in different dopaminergic nuclei however concomitant losses of other transmitters as noradrenaline and serotonin reflect a general underlying neurodegeneration. A number of studies have shown that ginsenosides can modulate neurotransmission in the brain. Both ginsenosides Rb\textsubscript{1} and Rg\textsubscript{1} can modulate acetylcholine release and re-uptake and the number of choline uptake sites especially in the hippocampus\textsuperscript{71}. They also increase choline acetyltransferase levels in rodent brains\textsuperscript{72}. Such data indicate that these compounds may improve central cholinergic function in humans and may be used to treat memory deficits\textsuperscript{59}. Ginsenosides increased dopamine and norepinephrine in cerebral cortex\textsuperscript{59} which may explain the favorable effects of ginseng extract upon attention, cognitive processing, integrated sensory-motor function and auditory reaction time in healthy subjects\textsuperscript{73,74}. Additionally, it has been shown that ginseng total saponins modulates dopaminergic activity at both presynaptic and postsynaptic receptors\textsuperscript{75}, and blocks behavioral sensitization induced by psychostimulants such as morphine\textsuperscript{76}, cocaine\textsuperscript{77}, methamphetamine\textsuperscript{78} and nicotine\textsuperscript{79}. Ginseng increased serotonin in the cortex\textsuperscript{80}, ginseng saponins raised the levels of biogenic amines in normal rat brain\textsuperscript{81}, ginsenoside Rg\textsubscript{2} directly interacted with nicotinic receptor subtypes\textsuperscript{82} and ginseng administration led to regulation of GABAergic transmission in animals\textsuperscript{83,84}.

**Effects of ginsenosides on cognitive decline**

Though the loss of motor functions is most evident at onset of PD, a concomitant decline of mental and cognitive functions has to be accepted. The use of herbal medicine, particularly ginseng, for improving cognitive performance has become increasingly popular during recent years and some studies have shown its enhancing effects on learning and memory either in aged and/or brain damaged individuals\textsuperscript{85,86}. For example, significant improvement in learning and memory has been observed in aged and brain-damaged rats after local administration of ginseng powder\textsuperscript{87}. In humans, Terasawa et al.\textsuperscript{88} have shown that ginseng or ginseng extract had significant effects on neurological and psychiatric symptoms in aged humans and psychomotor functions in healthy subjects respectively. This positive effect of ginseng on cognition performance is owing to the direct action of ginseng on the hippocampus\textsuperscript{89}. Moreover, Shen and Zhang\textsuperscript{90} suggested that the influence of ginsenoside Rg\textsubscript{2} on the proliferating ability of neuronal progenitor cells may serve as an important mechanism underlying its nootropic and anti-aging effects particularly on learning and memory.
This still appears controversial, as in healthy individuals Persson et al. \(^{51}\) reported that regular use of ginseng during long period of time (up to 2 years) by healthy participants did not provide quantifiable beneficial effects on memory performance.

**Concluding remarks**

The worldwide use of ginseng as a medical herb and its intake by many healthy individuals to invigorate their bodies are based primarily on its empirical history in contributing to the recovery from a wide range of disease conditions particularly in the Far East countries. Yet, recent experimental research provides detailed indications of neuroprotective properties in cell culture systems and animal studies.

Parkinson’s disease is a chronic neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra. The destruction of the dopaminergic system results in diminished dopamine levels in the striatum, the main target of dopaminergic projections. The actual treatment of parkinsonism is aimed at stopping nigral cell death (“neuroprotection”) or to restore the function of remaining neurons (“neurorestoration”).

To date, only the relief of Parkinsonian symptoms, particularly in the first five years after onset of the disease, has been achieved with levodopa, the dopamine precursor. Although levodopa replacement therapy is effective to compensate loss of dopamine in the striatum, the initial success is soon overshadowed by decreased efficacy and appearance of motor complications. Thus for PD it appears essential to affect the slow progressive loss of dopaminergic neurons caused by oxidative stress, excitotoxicity, neuroinflammation and possibly also long term medication. Ginsenosides are compounds which have been shown in neuronal cell cultures and animal models to counteract these phenomena. Though such data are stimulating, it is clearly a long way from in vitro data to proven neuroprotective action in a human disease. It will remain to validated data from the clinic and here particularly imaging techniques as to actually prove, if the postulated neuroprotective actions of ginseng and/or their ingredients have such a desired effectivity in neurodegenerative disorders as PD.

**REFERENCES**


16. Murer, M. G., Dziewczapolski, G., Menalled, L. B., Garcia, M. C., Agid Y., Gershankik, O. and Raisman-Vozari, R.: Chronic levodopa is not toxic for remaining dopamine neu-


Perspectives for Ginsenosides in Models of Parkinson’s Disease


